JPMorgan lowered the firm’s price target on Hims & Hers to $33 from $35 and keeps an Overweight rating on the shares. The company reported “mixed” Q1 results and updated its 2026 outlook to reflect the strategic GLP-1 shift from compounded to branded, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Hims & Hers price target raised to $28 from $24 at Citi
- Closing Bell Movers: Hims & Hers down 12% on earnings miss
- HIMS Earnings: Hims & Hers Stock Falls 10% as Financial Results Miss Wall Street Targets
- Bullish flow in Hims and Hers Health with shares up 3.13%
- Notable companies reporting after market close